Clinical Context & Research Overview Important: Peptide therapy for metabolic support should be discussed with a licensed clinician
Consequently, it is crucial to explore alternative therapeutic options for managing these seizures
As previously mentioned, GLP-1 users report dining out less frequently, corresponding with an increase in users who are cooking dinner at home
[16] Second, and most distinctively, T4 stimulates oligodendrocyte-progenitor differentiation and remyelination , apparently via p38 MAPK signaling, across stroke, TBI, and EAE models
The criteria for both Mounjaro and Wegovy are: BMI of 30 or above, or BMI of 27 or above with at least one weight-related health condition (such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea) If your BMI is below 27, you wont currently be eligible for GLP-1 medication for weight management through the NHS or private prescribers in the UK 7,8
other lymphadenopathy persisting for 4-6 weeks Progressive growth : Nodes that continue to increase in size over time Hard, fixed, or irregular nodes : Lymph nodes that feel firm, immobile, or have an irregular texture may indicate serious pathology Generalised lymphadenopathy : Swelling in multiple lymph node regions (neck, armpits, groin) simultaneously Systemic symptoms : Unexplained fever, drenching night sweats, unintentional weight loss (beyond expected GLP-1-related weight reduction), or persistent fatigue Associated symptoms : Difficulty swallowing, breathing difficulties, or hoarseness accompanying neck lymphadenopathy According to NICE guideline NG12 , lymphadenopathy with concerning features should prompt consideration of a suspected cancer pathway referral (2-week wait)
